Larisa Aleksandrovna Rogozina

Larisa Aleksandrovna Rogozina

Auto-generated profile, based on publicly available information

Larisa Aleksandrovna Rogozina

Samara State Medical University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Ulyanovsk Medico-biological Journal
Verified
Journal Article
Closed access
LRLarisa Aleksandrovna Rogozina
Larisa Aleksandrovna Rogozina
IDIgor' Leonidovich Davydkin
Igor' Leonidovich Davydkin
OFOleg Veniaminovich Fatenkov
Oleg Veniaminovich Fatenkov
ODOlesya Evgen'EVna Danilova
Olesya Evgen'EVna Danilova
RKRais Kettdusovich Khayretdinov
Rais Kettdusovich Khayretdinov
GGGeliya Rifkatovna Gimatdinova
Geliya Rifkatovna Gimatdinova
Atypical hemolytic uremic syndrome (aHUS) is a systemic disease, a type of thrombotic microangiopathy (TMA). It is based on uncontrolled activation of the alternative complement pathway of a hereditary or acquired nature, leading to generalized thrombosis in the microvasculature. Chronic activation of the alternative complement pathway leads to the damage of endothelial cells, erythrocytes and platelets and, as a result, to thrombotic microangiopathy and systemic multiorgan damage. Currently, in roughly half of the cases, it is impossible to identify aHUS triggers. Fresh frozen plasma (FFP) is used as first-line drug to reverse the symptoms. It helps to eliminate the deficiency of self-proteins – complement factor H and complement factor I (CFH and CFI), membrane cofactor protein (MCP), and stable and labile proteins – factors of hemostasis, and to stop thrombosis in the microvasculature. FFP administration is a preparatory step before anticomplementary therapy. Disease prognosis is always serious and is associated with severe complications and high mortality. At least 6 % of patients develop multiple organ failure with generalized TMA, injury of the central nervous system, gastrointestinal tract, lungs, and kidneys. The paper describes a clinical case of a patient with aHUS.

11 March 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
IDI. L. Davydkin
I. L. Davydkin
ТКТ. П. Кузьмина
Т. П. Кузьмина
IZI. A. Zolotovskaya
I. A. Zolotovskaya
OTO. V. Tereshina
O. V. Tereshina
ODO. E. Danilova
O. E. Danilova
LRL. A. Rogozina
L. A. Rogozina
Aim. To assess eft ventricular (LV) contractility dysfunction in patients with chronic lymphocytic leukemia (CLL) receiving chemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), and to determine the enalapril.effectiveness for their treatment.Material and methods. The study included 49 patients with newly diagnosed Binet stage B CLL in combination with class I-II stable angina, stage 1-2 hypertension and LV ejection fraction (EF) >50%. All subjects did not take angiotensin converting enzyme inhibitors (ACE inhibitors), had no clinical signs of heart failure (HF), and all had indications for FCR combination use before study start. Patients underwent two-dimensional echocardiography initially, before starting chemotherapy (period V1) and after three (84±5 days) (V2) and six (168±7 days) (V3) courses of chemo therapy (enalapril) was added to the treatment regimen in the experimental group.Results. After the third course of chemotherapy, a relative percentage decrease in global longitudinal strain (GLS) was noted in the experimental and control groups — by 16,16±0,80 and 16,2±0,79, respectively (p=0,764). These changes are considered a cardiotoxicity predictor. At the same time, LVEF values remained within the normal range: 63,4% [65; 68] in the experimental group and 63,9% [61,6; 67] in the control group (p=0,960). After the sixth course, LVEF values significantly differed (p=0,002): in the control group, five patients (21%) had cardiotoxicity; in experimental group, there were no patients with cardiotoxicity.Conclusion. A clinically significant decrease in GLS is a marker of subclinical LV contractile dysfunction and is a cardiotoxicity predictor in CLL patients receiving chemotherapy with FCR. The timely addition of enalapril to the treatment regimen can prevent cardiotoxicity in such patients. The need for early assessment of GLS during FCR courses for the detection and prevention of cardiotoxicity has been proved.

30 June 2026 in Dalʹnevostočnyj medicinskij žurnal
Verified
Journal Article
Closed access
OROlesya Rubanenko
Olesya Rubanenko
LRLarisa A. Rogozina
Larisa A. Rogozina
VTViktoria I. Titenko
Viktoria I. Titenko
VKViktoria E. Kochurova
Viktoria E. Kochurova

9 March 2026 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Closed access
PDF file
LRL. A. Rogozina
L. A. Rogozina
OVOLGA VOROBYEVA
OLGA VOROBYEVA
IGIu. A. Gergel
Iu. A. Gergel
TNT. E. Nichik
T. E. Nichik
IDI. L. Davydkin
I. L. Davydkin
Globally, the prevalence of chronic kidney disease (CKD) is approaching epidemic levels. Some CKD phenotypes of secondary etiology are characterized by slow progression with a prolonged period of asymptomatic progression, does not reach nephrotic levels. Assessing prognostic markers in the early stages of CKD is essential to reduce the risk of progression to kidney dysfunction and cardiovascular disease through timely pathogenetic correction. This should be addressed not only by nephrologists but also by other primary care practitioners. This article describes a 64-year-old male patient with obesity, episodes of hyperglycemia, and long-standing arterial hypertension. Biochemical analysis confirms hyperglycemia, hyperuricemia, and dyslipidemia. Morphological studies indicate the development of secondary segmental glomerulosclerosis, including in the vascular pole of the glomeruli. Autoimmune pathology has been excluded. Urinalysis revealed episodes of proteinuria up to 4.2 g per day. After adequate treatment of hypertension, dyslipidemia, hyperglycemia, and hyperuricemia, a decrease in proteinuria was observed. The evaluation and treatment of these patients requires a comprehensive approach, with the mandatory participation of nephrologists and endocrinologists.when proteinuria